About
Surrozen Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address severe diseases, leveraging its proprietary SIRPa-IgG platform for targeted immune response modulation. The company's robust pipeline includes groundbreaking antibody therapeutics primarily aimed at oncology and autoimmune disorders, reflecting its commitment to fulfilling significant unmet medical needs. Bolstered by strategic partnerships and a strong emphasis on research and development, Surrozen is strategically positioned to advance transformative therapies, marking it as a promising player within the biopharmaceutical landscape with substantial growth potential.
Advanced charting, extended hours trading, and free stock for new accounts.
Price data sourced from Polygon.io (previous trading day close). Fundamentals from Alpha Vantage. Insider trades from SEC EDGAR. Cached via Cloudflare KV.